Navigation Links
Eularis Exposes Hidden Barriers to Patient Adherence With New Pharmaceutical Industry Report
Date:3/12/2008

Non-Adherence Shown to Significantly Impact Patient Health and Financial

Performance of Pharmaceutical Companies

NEW YORK and LONDON, March 12 /PRNewswire/ -- Costing the global pharmaceutical industry an estimated $30 billion per year and causing an estimated 125,000 deaths per year in the United States, patient non-adherence is a looming issue in the healthcare industry. Eularis has responded to this problem with a new report, available today, titled, "Ensuring Profitable Patient Adherence Programs." This report analyzes the underlying barriers to patient compliance and studies how pharmaceutical companies can implement successful adherence programs that will improve patient care while also increasing profitability.

*(LOGO 72dpi: Send2Press.com/mediaboom/07-0924-Eularis_72dpi.jpg)

Written for CEOs, marketing executives and sales executives, this report uncovers that while adherence programs are designed to target the obvious reasons for non-compliance, including lack of insurance coverage, poor doctor-patient communication, preference for alternative therapies or simply forgetting, they are often ineffective. The report suggests that this is because there are barriers in the pharmaceutical companies themselves that may be hindering compliance program success. These barriers include such things as siloed organizational structures, privacy issues, short lifecycle of brand managers and difficulty of measuring return on investment.

"Pharmaceutical companies need to reconsider their approach to solving the patient adherence problem and stop viewing non-compliance as 'the patient's problem,'" commented Dr. Andree K. Bates, author of the report and president of Eularis. "In order to implement successful adherence programs that will improve patient care and increase profitability, companies should take an analytical approach that examines all non-compliance data relating to each brand, including how that brand is managed and what the financial impact of non-compliance on that brand is before designing appropriate interventions."

An estimated 70 percent of patients who begin a pharmaceutical therapy discontinue it within one year, even those with chronic conditions that require ongoing treatment or those taking chemotherapy to prevent cancer recurrence. Given recent press reports of drug safety issues, as well as declining sales, greater competition, weaker pipelines, and increasing pressure to reduce direct-to-consumer (DTC) advertising, pharmaceutical companies can no longer ignore the hidden value available by increasing patient adherence.

The report identifies and provides insight into key elements that affect patient compliance, such as:

-- Underlying patient reasons for non-adherence

-- How pharmaceutical companies can measure the financial impact of

non-compliance

-- Program approaches for improving patient adherence

-- Tips for better patient-physician communication

-- Steps to increase patient adherence

The report also presents case studies that demonstrate how to effectively implement various adherence program approaches for several drug categories.

In closing, Bates said, "Adherence to prescribed medications, particularly for long-term therapies, poses a tremendous challenge to the world's pharmaceutical companies. Investigating brand-specific compliance rates, understanding the larger causative factors for lack of compliance, and developing and implementing programs to increase compliance can help brand managers increase market share and revenues for their brands while significantly improving clinical outcomes for patients."

Bates has gained wide recognition within the international pharmaceutical industry for her expertise in marketing return analysis. In addition to this and other must-have reports for pharmaceutical industry marketers, she has authored many articles in peer-reviewed journals and several chapters in books on pharmaceutical analytics.

To purchase the Eularis report, "Ensuring Profitable Patient Adherence Programs" visit: http://www.patientadherenceroi.com or for more information about Eularis visit http://www.eularis.com

About Eularis

Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches whose reliance on historical or analogue data reduces their accuracy, Eularis' proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate, and optimize their sales and marketing performance. Eularis offers pre-launch analytics, marketing mix modeling (both professional and consumer), portfolio optimization, sales force effectiveness, managed care analytics, and patient compliance solutions. Co-headquartered in London and New York City, the company has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

More information about Eularis: http://www.eularis.com.

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com.


'/>"/>
SOURCE Eularis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MEDIA ALERT: Eularis to Address Marketing Return at Measuring Marketing ROI in Pharma Conference in London
2. MEDIA ALERT: Eularis to Address Marketing Return at Pharmaceutical Marketing Society Half-day Conference: ROI or RIP?
3. Eularis Releases Update of Its Comprehensive Report on Maximizing the Bottom Line in Pharmaceutical Marketing
4. Eularis Announces New Corporate Name and Expanded Product Offerings
5. New Mini-Documentary Exposes Psychiatric Drugs Turning Kids into Killers
6. New Legal Momentum Publication Exposes How Abstinence-Only Programs Harm Women and Girls
7. Walter Reed Anniversary Exposes More McCain Double Talk
8. With the Largest-Ever Buyout of a National Nursing Home Chain Pending ... New York Times Exposes Harm to Seniors After Private Equity Buyouts of Nursing Homes
9. New York Times Exposes Harm to Seniors After Private Equity Buyouts of Nursing Homes
10. Hidden Epidemic of Congestive Heart Failure Driving Hospitalization, Costs
11. Routine screenings uncover hidden carbon monoxide poisoning
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... ... 2017 , ... A New York high tech innovator and a Canadian not-for-profit ... of Artificial Intelligence (AI) in helping nudge men forward to be more proactive about ... of the Canadian Men’s Health Foundation (CMHF), whose mission is to inspire men to ...
(Date:5/28/2017)... ... ... HYPERAMS, LLC announced it will perform the inventory liquidation of ... The sale began this week and the inventory is expected to sell quickly. ... medical accessories, including blood pressure cuffs, stethoscopes, CPR masks, as well as blank polos, ...
(Date:5/28/2017)... ... 28, 2017 , ... Viewers likely know Rob Lowe from such 80s hits ... for his work on NBC’s The West Wing and Parks and Recreation. But recently, ... “Informed,” which puts the spotlight on important modern-day issues that face today’s society. One ...
(Date:5/27/2017)... ... ... In any business, follow up is critical to success. It is the same ... there will always be some patients who can’t or won’t make a immediate decision. ... it comes to presenting treatment. After the patient leaves, most practices end up ...
(Date:5/26/2017)... NY (PRWEB) , ... May 26, 2017 , ... Mediaplanet ... & Wound Care" campaign in USA Today, which will educate readers on how to ... of the campaign, a large focus is placed on melanoma. Dancing with the Stars ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... Md. , May 10, 2017 CSSi, ... solutions for the clinical research industry, is proud to ... www.CSSiEnroll.com . The new website features both enriched content ... user experience and enhances the company,s already well-established position ... industry. "After many months of hard ...
(Date:5/9/2017)... , May 9, 2017  Semler Scientific, ... provides technology solutions to improve the clinical effectiveness ... results for the first quarter ended March 31, ... products enable our customers to identify when preventive ... intervene before events like heart attacks or strokes ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke ... one of the most important methods to prevent a ... the Centers for Disease Control and Prevention, undetected and ... 1 Omron, the global leader in personal heart ... the elimination of heart attack and stroke and is ...
Breaking Medicine Technology: